InvestSMART

Paradigm Biopharmaceuticals Limited (ASX: PAR) - Announcements

- Current share price for PAR : $0.175

ASX company news and announcements for Paradigm Biopharmaceuticals Limited (PAR) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Paradigm Biopharmaceuticals Limited (PAR) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Paradigm Biopharmaceuticals Limited (PAR), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Paradigm Biopharmaceuticals Limited (PAR)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$106 PARADIGM RECEIVES $2.32m R&D TAX INCENTIVE REFUND 15 Nov 2018 8:29AM $0.895 $0.178 fallen by 80.17%
$106 PAR reports pain reduction in 145 people with osteoarthritis 7 Nov 2018 11:00AM $1.040 $0.178 fallen by 82.93%
$106 Cleansing Notice and Appendix 3B 1 Nov 2018 12:14PM $0.850 $0.178 fallen by 79.12%
$106 Quarterly Report and Appendix 4C - quarterly 31 Oct 2018 9:27AM $0.910 $0.178 fallen by 80.49%
$106 Notice of Annual General Meeting/Proxy Form 26 Oct 2018 4:49PM $0.830 $0.178 fallen by 78.61%
$106 Paradigm Agreement With USA Past Players Network 25 Oct 2018 9:02AM $0.730 $0.178 fallen by 75.68%
$106 Paradigm's Updated Corporate Presentation 25 Oct 2018 8:59AM $0.730 $0.178 fallen by 75.68%
$106 Paradigm Raises A$9 Million 25 Oct 2018 8:57AM $0.730 $0.178 fallen by 75.68%
$106 Trading Halt 23 Oct 2018 9:15AM $0.730 $0.178 fallen by 75.68%
$106 PAR REPORTS PAIN REDUCTION IN OA PATIENTS 25 Sep 2018 8:28AM $0.890 $0.178 fallen by 80.06%
$106 Phase2a RossRiver Virus Clinical Trial Recruitment Finalised 28 Aug 2018 12:04PM $0.970 $0.178 fallen by 81.70%
$106 Appendix 4G and Corporate Governance Statement 24 Aug 2018 4:25PM $0.990 $0.178 fallen by 82.07%
$106 Appendix 4E and 2018 Annual Report 24 Aug 2018 4:20PM $0.990 $0.178 fallen by 82.07%
$106 PAR ACHIEVES 60 PER CENT REDUCTION IN OSTEOARTHRITIS PAIN 15 Aug 2018 8:09AM $0.815 $0.178 fallen by 78.22%
$106 Cleansing Notice and Appendix 3B 8 Aug 2018 4:39PM $0.820 $0.178 fallen by 78.35%
$106 PAR achieves 100 per cent recruitment in Phase 2b OA Trial 6 Aug 2018 9:16AM $0.885 $0.178 fallen by 79.94%
$106 Quarterly Report and Appendix 4C - quarterly 27 Jul 2018 4:03PM $0.910 $0.178 fallen by 80.49%
$106 Cleansing Notice and Appendix 3B 27 Jul 2018 3:52PM $0.915 $0.178 fallen by 80.60%
$106 Cleansing Notice and Appendix 3B 17 Jul 2018 5:17PM $0.960 $0.178 fallen by 81.51%
$106 Response to ASX Price Query 9 Jul 2018 9:06AM $0.830 $0.178 fallen by 78.61%
$106 Cleansing Notice and Appendix 3B 4 Jul 2018 5:18PM $0.700 $0.178 fallen by 74.64%
$106 Cleansing Notice and Appendix 3B 26 Jun 2018 4:24PM $0.645 $0.178 fallen by 72.48%
$106 Appendix 3B and Cleansing Notice 19 Jun 2018 4:25PM $0.610 $0.178 fallen by 70.90%
$106 PAR - 50% REDUCTION IN OSTEOARTHRITIS PAIN MAINTAINED 15 Jun 2018 8:29AM $0.680 $0.178 fallen by 73.90%
$106 Cleansing Notice 18 May 2018 5:07PM $0.525 $0.178 fallen by 66.19%

551 - 575 of 721 results

Page 23 of 29

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.